Sachin Pai, M.D., M.S.C.I.
Medical OncologistProgram Leader of Developmental Therapeutics; Assistant Professor of Interdisciplinary Clinical OncologySpecialty: Cancer CareConditions Treated
- Head and Neck Cancer
- Hypopharyngeal Cancer
- Laryngeal Cancer
- Lip and Oral Cavity Cancer
- Lung Cancer
- Mesothelioma
- Metastatic Squamous Neck Cancer
- Nasopharyngeal Cancer
- Neuroendocrine Tumors
- Oropharyngeal Cancer
- Paranasal Sinus and Nasal Cavity Cancer
- Salivary Gland Cancer
Professional Memberships
- American Association for Cancer Research (AACR)
- American Medical Association
- American Society of Clinical Oncology (ASCO)
Board Certifications
- American Board of Internal Medicine
- Certification in Medical Oncology
Education
- Medical School: Kasturba Medical College | Mangalore, India
- Residency: Louisiana State University Health Science Center | Shreveport, LA
- Fellowship: Ochsner Clinic Foundation | New Orleans, LA
- Fellowship: Northwestern Medicine Developmental Therapeutics Institute, Robert H. Lurie Comprehensive Cancer Center (RHLCCC) of Northwestern University | Chicago, IL
Languages
- English
- Hindi
Clinical Trials
[921786-3] PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth
Treatment for Breast Cancer
16-207 - [923977-5] Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs. Placebo in Combination with Capecitabine and Trastuzumab in Patients with Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma (HER2CLIMB)
Treatment for Breast Cancer
A Phase 3, Randomized, Global Trial of Nivolumab and Epacadostat with Platinum Doublet Chemotherapy versus Platinum Doublet Chemotherapy in First-line Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer
Treatment for Lung Cancer
A Prospective Quality of Life Study in Metastatic Pancreatic Cancer
Treatment for Pancreatic Cancer
A Phase III, Open-Label, Multicenter, Two-Arm, Randomized Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab Versus Pembrolizuman in Patients with Previously Untreated Advanced BRAF V600 Wild-Type Melanoma
Treatment for Melanoma
17-316 - CX-1158-101 Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Arginase Inhibitor CB-1158 as a Single Agent and in Combination with Immune Checkpoint Therapy in Patients with Advanced/Metastatic Solid Tumors
Treatment for Lung Cancer
18-029 - NRG-HN004: Randomized Phase II/III Trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) Vs. Radiotherapy with Concurrent Cetuximab in Patients with Stage III-IVB Head and Neck Cancer with a Contraindication to Cisplatin
Treatment for Head / Neck Cancer
18-004 - Phase II study of pembrolizumab and ipilimumab following initial anti-PD1/L1 antibody
Treatment for Melanoma
17-144 - Preoperative Extended Chemotherapy Vs. Chemotherapy Plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Head of the Pancreas
Treatment for Pancreatic Cancer
17-277 - Randomized, Open-label, Phase 3 Trial of Nivolumab plus Brentuximab vedotin versus Brentuximab vedotin alone in Participants with Relapsed Refractory or Ineligible for Autologous Stem Cell Transplant (ASCT) Advanced Stage Classical Hodgkin Lymph
Treatment for Hodgkin´s Lymphoma
17-147 - A Multicenter Phase 2 Study of the Glutaminase Inhibitor CB-839 in Combination with Paclitaxel in Patients with Advanced Triple Negative Breast Cancer (TNBC) Including Patients of African Ancestry and Non-African Ancestry
Treatment for Breast Cancer
Randomized Phase II Study of 2nd Line FOLFIRI versus Modified FOLFIRI with PARP Inhibitor ABT-888 (Veliparib) (NSC-737664) in Metastatic Pancreatic Cancer.
Treatment for Pancreatic Cancer
This clinical trial studies nivolumab and ipilimumab in treating patients with rare tumors. Monoclonal antibodies, such as nivolumab and ipilimumab, may interfere with the ability of tumor cells to grow and spread.
Treatment for Rare Tumors
University of Chicago UC IRB17-0686 Phase II study of pembrolizumab and ipilimumab following initial anti-PD1/L1 antibody
Treatment for Melanoma
[17-081 - 1031505-3] A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Subjects with Extensive Stage Small Cell Lung Cancer (MERU)
Treatment for Lung Cancer